Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
Sponsor: Vivani Medical, Inc
Summary
The study will evaluate the safety, tolerability and drug levels of a semaglutide implant placed just under the skin for a period of 4 weeks compared to 4 weekly injections of semaglutide (Wegovy) in overweight/obese participants who are otherwise healthy..
Official title: A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Semaglutide Implant
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-04
Completion Date
2026-09
Last Updated
2026-02-24
Healthy Volunteers
No
Conditions
Interventions
Semaglutide Implant (NPM-139)
Semaglutide Implant (NPM-139) is a drug/device combination product consisting of a subdermal titanium implant \~23 mm long and 2 mm in diameter, containing a sterile liquid formulation of semaglutide that is released from the implant at a substantially constant rate over at least 15 weeks.
Semaglutide (Wegovy) weekly injection
Semaglutide (Wegovy) is a clear, colorless solution provided as Wegovy FlexTouch four-dose pens: 0.25 mg/0.5 mL. It is injected SC in the abdomen, thigh or upper arm once/week.